Article ID Journal Published Year Pages File Type
3382663 Personalized Medicine Universe 2012 8 Pages PDF
Abstract
DC vaccine-based immunotherapy demonstrates promising OS times and tolerable toxicities in the setting of breast carcinoma. A full risk/benefit analysis of DC-based vaccines in patients with metastatic breast carcinoma will be determined in a future phase II trial.
Keywords
Related Topics
Health Sciences Medicine and Dentistry Immunology, Allergology and Rheumatology
Preview
Retrospective analysis of the clinical efficacy of a dendritic cell-based cancer vaccine in patients with advanced or recurrent breast cancer
Authors
, , , , ,